Lang Irene M
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna Vienna, Austria.
Eur Cardiol. 2023 Apr 5;18:e11. doi: 10.15420/ecr.2022.29. eCollection 2023.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare major vessel pulmonary vascular disease that is characterised by fibrotic obstructions deriving from an organised clot. Recent advances in treatments for CTEPH have significantly improved outcomes. Apart from classical surgical pulmonary endarterectomy, balloon pulmonary angioplasty (BPA) and vasodilator drugs that were tested in randomised controlled trials of non-operable patients are now available. In Europe, CTEPH affects males and females equally. In the first European CTEPH Registry, women with CTEPH underwent pulmonary endarterectomy less frequently than men, especially at low-volume centres. In Japan, CTEPH is more common in females and is predominantly treated by BPA. More data on gender-specific outcomes are expected from the results of the International BPA Registry (NCT03245268).
慢性血栓栓塞性肺动脉高压(CTEPH)是一种罕见的大血管肺血管疾病,其特征是由机化血栓形成的纤维化阻塞。CTEPH治疗的最新进展显著改善了治疗效果。除了经典的外科肺动脉内膜剥脱术外,现在还可以使用在不可手术患者的随机对照试验中进行测试的球囊肺动脉血管成形术(BPA)和血管扩张药物。在欧洲,CTEPH对男性和女性的影响相同。在首个欧洲CTEPH登记处,患有CTEPH的女性接受肺动脉内膜剥脱术的频率低于男性,尤其是在手术量较少的中心。在日本,CTEPH在女性中更为常见,主要通过BPA进行治疗。国际BPA登记处(NCT03245268)的结果有望提供更多关于性别特异性治疗效果的数据。